Adimab
Adimab is the most successful antibody discovery and engineering company in the industry. Since 2007, we’ve collaborated with industry and academic institutions to generate high-quality therapeutic leads across a wide range of targets and formats. Our yeast-based platform enables end-to-end discovery, optimization, and developability assessment, delivering fully human IgGs, HCAbs, multispecifics, and engineered proteins, including TCRs, with speed and precision. We have worked on 650+ discovery campaigns and generated 90+ clinical programs with 140+ partners.
